The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.
The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
4.
PARAXANTHINE-BASED COMPOSITIONS FOR INHIBITING INFLAMMATION, IMPROVING JOINT HEALTH, AND ENHANCING IMMUNE FUNCTION
The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The disclosed compositions, and methods relate to compositions for human consumption and comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
7.
PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
The disclosed compositions methods relate to a dietary supplement for subjects with slow caffeine metabolism and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite in a slow caffeine metabolizer subject.
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceuticals for use as a dietary supplement; dietary
supplements; nutraceuticals for use as an ingredient in the
manufacture of dietary supplements.
11.
THE USE OF PARAXANTHINE TO IMPROVE PERFORMANCE IN VIDEO GAMERS
Disclosed herein is a method for increasing video game performance in a subject by administering to the subject with a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. Further disclosed herein is a method for enhancing mood of a subject during electronic gameplay or preventing decrease in mood of a subject during electronic game play comprising administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, administration of the composition to the subject decreases, or prevents the increase of, one or more of tension, depression, anger, fatigue and/or confusion in the subject during electronic game play relative to a subject who has not been administered the composition.
A61K 36/35 - Caprifoliaceae (famille du chèvrefeuille)
A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Nutraceuticals for use as a dietary supplement for general health and well-being; dietary supplements for general health and well-being; nutraceuticals for use as an ingredient in the manufacture of dietary supplements for general health and well-being.
13.
THE USE OF PARAXANTHINE TO REDUCE EXERCISE-INDUCED MENTAL FATIGUE
Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.
Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 33/06 - Aluminium, calcium ou magnésiumLeurs composés
A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 33/04 - Soufre, sélénium ou tellureLeurs composés
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines; all of the aforementioned goods containing caffeine Nutraceuticals for use as a dietary supplement; dietary supplements; all of the aforementioned goods containing caffeine
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines Nutraceuticals for use as a dietary supplement; dietary supplements
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceuticals for use as a dietary supplement; dietary
supplements; nutraceuticals for use as an ingredient in the
manufacture of dietary supplements.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Nutraceuticals for use as a dietary supplement for general health and well-being; dietary supplements, namely dietary and nutritional supplements for general health and well being; nutraceuticals for use as an ingredient in the manufacture of dietary supplements for general health and well being
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines Nutraceuticals for use as a dietary supplement; dietary supplements
